Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

cost and value

market access in Japan

Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

Petauri Evidence

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

Democrats in the US agree plan to curb drug prices

House Democrats have added a measure to curb prescription drug costs to President Biden’s $1.85tr social safety net plan

- PMLiVE

Policy and public health: all the decisions we can’t see

January was a bad month for healthcare in China

- PMLiVE

Trump presses on with reference pricing plan for medicines

Proposed pilot programme to run until 2025

- PMLiVE

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

US among those in favour of price transparency

- PMLiVE

Tit for tat as PBMs blame pharma for high drug prices

US Senate turns its spotlight on 'middlemen'

- PMLiVE

Gottlieb signs off with flair – and pledge of further drug price commentary

Highlights issues of insulin prices and competition

- PMLiVE

Trump budget targets rebates, out-of-pocket costs

Biotech sector welcomes end to rebates, but worries about Medicare cuts

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

- PMLiVE

Fireworks likely at Senate drug pricing hearing today

Senators fire broadsides: "I hope CEOs don't blame everyone but themselves"

- PMLiVE

CEOs agree to Congressional grilling on US drug prices

Tough questions await pharma bosses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links